$150K — $200K *
Deciphera Pharmaceuticals is a commercial biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates in clinical studies, QINLOCK is Deciphera's first FDA-approved drug, a switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK, an oral oncolytic, is also approved in Canada and Australia for the treatment of fourth-line GIST.
Deciphera (NASDAQ: DCPH) is a publicly traded company headquartered in Waltham, Massachusetts. Our state-of-the-art research facility is located in Lawrence, Kansas.
We offer an outstanding culture and opportunity for personal and professional growth based on our "PATHS" Core Values:
- Patients - places the importance of improving the lives of patients and their caregivers at the forefront of every day's work.
- Accountability - for our performance and the way we work with coworkers and other stakeholders.
- Transparency - in our intent and actions to both internal and external stakeholders.
- Honesty and Integrity - fosters trust and strives to deliver on our and the company's promises.
- Stewardship - values and uses wisely the resources and investments provided to the company.
Our Science and Our Pipeline:
Deciphera is developing novel small molecule drug candidates to improve the lives of cancer patients by addressing key mechanisms of tumor and drug resistance that limit the effectiveness of many cancer therapies. Our pipeline of drug candidates is designed to stop cancers from growing and spreading by inhibiting mutant forms or over expression of a family of enzymes called kinase. Enabled by our proprietary kinase switch control inhibitor drug discovery platform, we have developed kinase switch control inhibitors that interact at a molecular level in a way that is distinct from other kinase inhibitors and are designed to generate higher and more durable rates of response.
We have developed a diverse pipeline of differentiated, wholly owned, orally administered, oncology drug candidates that includes, among others, our recently approved product, QINLOCK (ripretinib), a broad-spectrum KIT and PDGFRa kinase switch control inhibitor is approved for the treatment of fourth-line GIST. Our follow-on study of ripretinib, the INTRIGUE study, is a pivotal Phase 3 trial in second-line GIST. We also have two additional clinical-stage programs for drug candidates DCC-3014 and rebastinib, both immune-oncology (or immunokinase) inhibitors, targeting the kinases CSF1R and TIE2 respectively. Two research-stage programs are in the pipeline as well.
Valid through: 4/3/2021